Mondrian Investment Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Mondrian Investment Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,401	Closed	-$45K	–	111
2022 Q1	$45K	Sell	1,401 -138,933	-99%	-$4.26M	﹤0.01%	104
2021 Q4	$4.09M	Hold	140,334	–	–	0.08%	70
2021 Q3	$3.74M	Buy	140,334 +47,229	+51%	+$1.27M	0.08%	71
2021 Q2	$2.87M	Hold	93,105	–	–	0.05%	94
2021 Q1	$2.83M	Buy	+93,105	New	+$2.6M	0.06%	91

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Mondrian Investment Partners's SUPN Position: Q2 2022 in Review

Mondrian Investment Partners sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 1,401 shares — an estimated $45K sold.

Mondrian Investment Partners first reported a position in SUPN in Q1 2021 and held it in 5 quarters. The position peaked at $4.09M in Q4 2021. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

Mondrian Investment Partners reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Mondrian Investment Partners sold 1,401 Supernus Pharmaceuticals shares in Q2 2022, an estimated $45K.
Mondrian Investment Partners first reported a position in Supernus Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Mondrian Investment Partners's Supernus Pharmaceuticals position peaked at $4.09M in Q4 2021.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on Mondrian Investment Partners's 13F filing for Q2 2022, filed 9 Aug 2022.